Cash and cash equivalents were $150.4 million as of March 31, 2025, compared to $176.3 million as of December 31, 2024. The company expects that current cash, cash equivalents and short-term investments as of March 31, 2025, will be sufficient to fund its operating expenses into the second half of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Appoints Michael Grissinger to Board
- Adicet Bio’s ADI-001: A Promising Off-the-Shelf Therapy with Positive Outlook
- Adicet Bio’s Innovative CAR γδ T Cell Therapies: A Promising Buy Rating Amidst Upcoming Phase 1 Data and Market Positioning
- Buy Recommendation for Adicet Bio’s ADI-001: Promising Potential in Autoimmune Disease Treatment
- Promising Pipeline and Strong Financials Drive Buy Rating for Adicet Bio